drugset / Trial / NCT01225575

Assessment of Efficacy and Safety of 3 Different Doses of co.Don Chondrosphere to Treat Large Cartilage Defects

NCT01225575 ↗

Phase 2 Completed 75 enrolled co.don AG
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomised, open label, multicentre Phase II clinical trial to investigate the efficacy and safety of the treatment of large defects with 3 different doses of the autologous chondrocyte transplantation product co.don chondrosphere® (ACT3D-CS) in subjects with cartilage defects of the knee. After screening visit patients were booked for arthroscopy and had their cells harvesting from healthy cartilage. After the arthroscopy the patients were randomised in one of the three dose-groups. The cells are cultivated for 8-10 weeks in vitro to develope 3-dimensional spheroids, that are transplanted in an open knee procedure (treatment surgery)into the defect. Patients of all dose groups subsequently followed the same rehabilitation program and had post-surgery visits. The 12-month-visit is defined as final assessment. Then patients have follow-up assessments up to 60 months.

Timeline

Start
2010-10
Primary completion
2013-09
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator co.don chondrosphere® Cell therapy 3 unknown Other
Comparator co.don chondrosphere® Cell therapy 7 unknown Other
Comparator co.don chondrosphere® Cell therapy 10 unknown Other
Comparator co.don chondrosphere® Cell therapy 30 unknown Other
Comparator co.don chondrosphere® Cell therapy 40 unknown Other
Comparator co.don chondrosphere® Cell therapy 70 unknown Other

Indications

No indication recorded.